Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size, Status and Forecast 2021-2027

Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size, Status and Forecast 2021-2027

Table of Contents
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Transthyretin Stabilizers
1.2.3 Nonsteroidal Anti-inflammatory Drugs (NSAID)
1.2.4 RNAi Therapy
1.2.5 Others
1.3 Market by Application
1.3.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hereditary Transthyretin Amyloidosis (hATTR)
1.3.3 Wild Type Transthyretin Amyloidosis (wtATTR)
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Perspective (2016-2027)
2.2 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Growth Trends by Regions
2.2.1 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Historic Market Share by Regions (2016-2021)
2.2.3 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Forecasted Market Size by Regions (2022-2027)
2.3 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Industry Dynamic
2.3.1 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Trends
2.3.2 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Drivers
2.3.3 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Challenges
2.3.4 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Players by Revenue
3.1.1 Global Top Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Players by Revenue (2016-2021)
3.1.2 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Market Share by Players (2016-2021)
3.2 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue
3.4 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Concentration Ratio
3.4.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue in 2020
3.5 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Key Players Head office and Area Served
3.6 Key Players Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Solution and Service
3.7 Date of Enter into Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Breakdown Data by Type
4.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Historic Market Size by Type (2016-2021)
4.2 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Forecasted Market Size by Type (2022-2027)
5 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Breakdown Data by Application
5.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Historic Market Size by Application (2016-2021)
5.2 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size (2016-2027)
6.2 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type
6.2.1 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2021)
6.2.2 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2022-2027)
6.2.3 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2027)
6.3 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application
6.3.1 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2016-2021)
6.3.2 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2022-2027)
6.3.3 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2016-2027)
6.4 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country
6.4.1 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2016-2021)
6.4.2 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size (2016-2027)
7.2 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type
7.2.1 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2021)
7.2.2 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2022-2027)
7.2.3 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2027)
7.3 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application
7.3.1 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2016-2021)
7.3.2 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2022-2027)
7.3.3 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2016-2027)
7.4 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country
7.4.1 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2016-2021)
7.4.2 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size (2016-2027)
8.2 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type
8.2.1 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2027)
8.3 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application
8.3.1 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2016-2027)
8.4 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Region
8.4.1 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size (2016-2027)
9.2 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type
9.2.1 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2021)
9.2.2 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2022-2027)
9.2.3 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2027)
9.3 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application
9.3.1 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2016-2021)
9.3.2 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2022-2027)
9.3.3 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2016-2027)
9.4 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country
9.4.1 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2016-2021)
9.4.2 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size (2016-2027)
10.2 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type
10.2.1 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2027)
10.3 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application
10.3.1 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2016-2027)
10.4 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country
10.4.1 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Pfizer Inc
11.1.1 Pfizer Inc Company Details
11.1.2 Pfizer Inc Business Overview
11.1.3 Pfizer Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Introduction
11.1.4 Pfizer Inc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021)
11.1.5 Pfizer Inc Recent Development
11.2 GlaxoSmithKline Plc
11.2.1 GlaxoSmithKline Plc Company Details
11.2.2 GlaxoSmithKline Plc Business Overview
11.2.3 GlaxoSmithKline Plc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Introduction
11.2.4 GlaxoSmithKline Plc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021)
11.2.5 GlaxoSmithKline Plc Recent Development
11.3 Eidos Therapeutics
11.3.1 Eidos Therapeutics Company Details
11.3.2 Eidos Therapeutics Business Overview
11.3.3 Eidos Therapeutics Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Introduction
11.3.4 Eidos Therapeutics Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021)
11.3.5 Eidos Therapeutics Recent Development
11.4 Ionis Pharmaceuticals, Inc
11.4.1 Ionis Pharmaceuticals, Inc Company Details
11.4.2 Ionis Pharmaceuticals, Inc Business Overview
11.4.3 Ionis Pharmaceuticals, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Introduction
11.4.4 Ionis Pharmaceuticals, Inc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021)
11.4.5 Ionis Pharmaceuticals, Inc Recent Development
11.5 Alnylam Pharmaceuticals
11.5.1 Alnylam Pharmaceuticals Company Details
11.5.2 Alnylam Pharmaceuticals Business Overview
11.5.3 Alnylam Pharmaceuticals Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Introduction
11.5.4 Alnylam Pharmaceuticals Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021)
11.5.5 Alnylam Pharmaceuticals Recent Development
11.6 Prothena Corporation Plc
11.6.1 Prothena Corporation Plc Company Details
11.6.2 Prothena Corporation Plc Business Overview
11.6.3 Prothena Corporation Plc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Introduction
11.6.4 Prothena Corporation Plc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021)
11.6.5 Prothena Corporation Plc Recent Development
11.7 Intellia Therapeutics, Inc
11.7.1 Intellia Therapeutics, Inc Company Details
11.7.2 Intellia Therapeutics, Inc Business Overview
11.7.3 Intellia Therapeutics, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Introduction
11.7.4 Intellia Therapeutics, Inc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021)
11.7.5 Intellia Therapeutics, Inc Recent Development
11.8 Corino Therapeutics, Inc
11.8.1 Corino Therapeutics, Inc Company Details
11.8.2 Corino Therapeutics, Inc Business Overview
11.8.3 Corino Therapeutics, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Introduction
11.8.4 Corino Therapeutics, Inc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021)
11.8.5 Corino Therapeutics, Inc Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
Table 1. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Transthyretin Stabilizers
Table 3. Key Players of Nonsteroidal Anti-inflammatory Drugs (NSAID)
Table 4. Key Players of RNAi Therapy
Table 5. Key Players of Others
Table 6. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Regions (2016-2021) & (US$ Million)
Table 9. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Regions (2016-2021)
Table 10. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 11. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Regions (2022-2027)
Table 12. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Trends
Table 13. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Drivers
Table 14. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Challenges
Table 15. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Restraints
Table 16. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue by Players (2016-2021) & (US$ Million)
Table 17. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Players (2016-2021)
Table 18. Global Top Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment as of 2020)
Table 19. Ranking of Global Top Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Companies by Revenue (US$ Million) in 2020
Table 20. Global 5 Largest Players Market Share by Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue (CR5 and HHI) & (2016-2021)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Solution and Service
Table 23. Date of Enter into Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 26. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Market Share by Type (2016-2021)
Table 27. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 28. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 29. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Share by Application (2016-2021) & (US$ Million)
Table 30. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Market Share by Application (2016-2021)
Table 31. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 32. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 33. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 34. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 35. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2016-2021) (US$ Million)
Table 36. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 37. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 38. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 39. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 40. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 41. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2016-2021) (US$ Million)
Table 42. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 43. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 44. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 46. Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2016-2021) (US$ Million)
Table 48. Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Region (2016-2021) & (US$ Million)
Table 50. Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Region (2022-2027) & (US$ Million)
Table 51. Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 52. Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 53. Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2016-2021) (US$ Million)
Table 54. Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 55. Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 56. Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 58. Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2016-2021) (US$ Million)
Table 60. Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 62. Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 63. Pfizer Inc Company Details
Table 64. Pfizer Inc Business Overview
Table 65. Pfizer Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product
Table 66. Pfizer Inc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021) & (US$ Million)
Table 67. Pfizer Inc Recent Development
Table 68. GlaxoSmithKline Plc Company Details
Table 69. GlaxoSmithKline Plc Business Overview
Table 70. GlaxoSmithKline Plc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product
Table 71. GlaxoSmithKline Plc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021) & (US$ Million)
Table 72. GlaxoSmithKline Plc Recent Development
Table 73. Eidos Therapeutics Company Details
Table 74. Eidos Therapeutics Business Overview
Table 75. Eidos Therapeutics Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product
Table 76. Eidos Therapeutics Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021) & (US$ Million)
Table 77. Eidos Therapeutics Recent Development
Table 78. Ionis Pharmaceuticals, Inc Company Details
Table 79. Ionis Pharmaceuticals, Inc Business Overview
Table 80. Ionis Pharmaceuticals, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product
Table 81. Ionis Pharmaceuticals, Inc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021) & (US$ Million)
Table 82. Ionis Pharmaceuticals, Inc Recent Development
Table 83. Alnylam Pharmaceuticals Company Details
Table 84. Alnylam Pharmaceuticals Business Overview
Table 85. Alnylam Pharmaceuticals Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product
Table 86. Alnylam Pharmaceuticals Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021) & (US$ Million)
Table 87. Alnylam Pharmaceuticals Recent Development
Table 88. Prothena Corporation Plc Company Details
Table 89. Prothena Corporation Plc Business Overview
Table 90. Prothena Corporation Plc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product
Table 91. Prothena Corporation Plc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021) & (US$ Million)
Table 92. Prothena Corporation Plc Recent Development
Table 93. Intellia Therapeutics, Inc Company Details
Table 94. Intellia Therapeutics, Inc Business Overview
Table 95. Intellia Therapeutics, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product
Table 96. Intellia Therapeutics, Inc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021) & (US$ Million)
Table 97. Intellia Therapeutics, Inc Recent Development
Table 98. Corino Therapeutics, Inc Company Details
Table 99. Corino Therapeutics, Inc Business Overview
Table 100. Corino Therapeutics, Inc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021) & (US$ Million)
Table 101. Corino Therapeutics, Inc Recent Development
Table 102. Research Programs/Design for This Report
Table 103. Key Data Information from Secondary Sources
Table 104. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Type: 2020 VS 2027
Figure 2. Transthyretin Stabilizers Features
Figure 3. Nonsteroidal Anti-inflammatory Drugs (NSAID) Features
Figure 4. RNAi Therapy Features
Figure 5. Others Features
Figure 6. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Application: 2020 VS 2027
Figure 7. Hereditary Transthyretin Amyloidosis (hATTR) Case Studies
Figure 8. Wild Type Transthyretin Amyloidosis (wtATTR) Case Studies
Figure 9. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Report Years Considered
Figure 10. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 11. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 12. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Regions: 2020 VS 2027
Figure 13. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Regions (2022-2027)
Figure 14. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Players in 2020
Figure 15. Global Top Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment as of 2020
Figure 16. The Top 10 and 5 Players Market Share by Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue in 2020
Figure 17. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Market Share by Type (2016-2021)
Figure 18. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Market Share by Type (2022-2027)
Figure 19. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 20. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Type (2016-2027)
Figure 21. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Application (2016-2027)
Figure 22. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Country (2016-2027)
Figure 23. United States Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Canada Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Type (2016-2027)
Figure 27. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Application (2016-2027)
Figure 28. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Country (2016-2027)
Figure 29. Germany Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. France Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. U.K. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Italy Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Russia Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Nordic Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Type (2016-2027)
Figure 37. Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Application (2016-2027)
Figure 38. Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Region (2016-2027)
Figure 39. China Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Japan Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. South Korea Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Southeast Asia Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. India Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Australia Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Type (2016-2027)
Figure 47. Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Application (2016-2027)
Figure 48. Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Country (2016-2027)
Figure 49. Mexico Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Brazil Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Type (2016-2027)
Figure 53. Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Application (2016-2027)
Figure 54. Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Country (2016-2027)
Figure 55. Turkey Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Saudi Arabia Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure

• Clinical Results in Diabetics To Be Boosted By Smart Artificial Beta Cells

For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…

• High-speed Data Transmission And High Volume Needs Propel Fiber Optic Connectors Market

Fiber optic connectors are a substantial fragment of the global telecommunication industry. Optical fibers are joined using fiber optic connectors, which allow the light conduction between two consecutive optical fibers. An additional im…

• Extensive Use of Digital Technologies for Diagnostic Applications To Boost Global Optical Imaging Market

The global optical imaging system market is predicted to reach US$ 3 billion by 2024. It is expected to grow at a stable rate and will post a CAGR of more than 8% in the coming years. The growing market infiltration of digital …

• Foremost Trends In Global Pet Care Market

The global pet care market is foretold to improve in the forthcoming years as matched to the preceding years and will showcase better sales in various market segments. It is estimated that the global pet care market will grow at a CAGR o…

• China To Review Its Food Security Laws

China has arisen as the globe’s firmest developing economy. In addition, China brags about the biggest population pool in the world. In recent times, the one child policy in the republic was terminated. This is anticipated to upsur…

Global Nuclear Medicine Cyclotron Systems Market Report, History and Forecast 2018-2029

Published: 11-Jan-2024        Price: US 3350 Onwards        Pages: 118

The global Nuclear Medicine Cyclotron Systems market was valued at US$ 220.85 million in 2022 and will reach US$ 283.75 million by the end of 2029, growing at a CAGR of 4.38% during 2023-2029. Asia-Pacific market for Nuclear Medicine Cyclotron Systems was valued at $ 61.16 million in 2022 and will reach $ 104.22 million by 2029, at a CAGR of 5.84% during the forecast period of 2023 through 2029. Report Scope This report aims to provide a comprehensive presentation of the glo......

Global Non-imaging Diagnostic Catheter Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 95

The global Non-imaging Diagnostic Catheter market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estim......

Global Imaging Diagnostic Catheter Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 90

The global Imaging Diagnostic Catheter market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estimated......

Global PCR Equipment Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 77

The global PCR Equipment market was valued at US$ 806 million in 2023 and is anticipated to reach US$ 1230.7 million by 2030, witnessing a CAGR of 6.7% during The forecast period 2024-2030. PCR (Polymerase Chain Reaction) equipment is widely used in molecular biology and genetics research for amplifying DNA and RNA sequences. The market for PCR equipment is influenced by several key drivers. Here are some of The significant market drivers: Advancements in Research and Diagnost......

Global Disposable Sterile Syringes and Needles Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 109

The global Disposable Sterile Syringes and Needles market was valued at US$ 404.4 million in 2023 and is anticipated to reach US$ 539.1 million by 2030, witnessing a CAGR of 2.1% during The forecast period 2024-2030. North American market for Disposable Sterile Syringes and Needles is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Disposable Sterile Syringes and N......

Global Orthopaedic Power Tools Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 106

The global Orthopaedic Power Tools market was valued at US$ 463.3 million in 2023 and is anticipated to reach US$ 746.5 million by 2030, witnessing a CAGR of 7.3% during The forecast period 2024-2030. North American market for Orthopaedic Power Tools is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Orthopaedic Power Tools is estimated to increase from $ million i......

Global Cerebrospinal Fluid Management Devices Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 86

The global Cerebrospinal Fluid Management Devices market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Cerebrospinal Fluid Management Devices is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Cerebrospinal Fluid Management Devices is estimate......

Global CAD & CAM Milling Burs Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 79

The global CAD & CAM Milling Burs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for CAD & CAM Milling Burs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for CAD & CAM Milling Burs is estimated to increase from $ million in 2023 to reach $ ......

Global Artificial Teeth Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 98

The global Artificial Teeth market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Artificial Teeth is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Artificial Teeth is estimated to increase from $ million in 2023 to reach $ million by 2030, a......

We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s. Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors. Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business. Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision. Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us. Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done. Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )

• Ad Hoc
• Pay - as - you - go / Bucket Subscriptions
• Fixed Cost for #of reports
• Customize / Personalize as per your needs